InMed Pharmaceuticals Appoints CBIZ as Auditor Following Marcum Acquisition, Addresses Previous Material Weakness

Reuters
2025/06/14
InMed Pharmaceuticals Appoints CBIZ as Auditor Following Marcum Acquisition, Addresses Previous Material Weakness

InMed Pharmaceuticals Inc. recently announced a change in its auditor due to the acquisition of Marcum LLP's attest business by CBIZ CPAs P.C. Marcum resigned as InMed's auditor, effective June 12, 2025, and CBIZ has been appointed as the new auditor for the fiscal year ending June 30, 2025. The resignation was not related to any disagreements or reportable events concerning InMed's financial statements, which did not contain any adverse opinions or disclaimers. However, a previously disclosed material weakness related to the adequacy of resources for responding to financial reporting matters was noted.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 255571) on June 13, 2025, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10